What was the DAPT length prescribed for high bleeding risk patients in the EVOLVE trial?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $24.99Unlock all

Practice for Clinical Training 1 (CT1) Day 4 Exam. Enhance your skills with a range of questions designed to test your clinical knowledge. Each question features detailed explanations to help you succeed.

Multiple Choice

What was the DAPT length prescribed for high bleeding risk patients in the EVOLVE trial?

Explanation:
The EVOLVE trial specifically evaluated dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary interventions, focusing on the balance between the risks of thrombotic events and bleeding complications. For high bleeding risk patients, the trial showed that a shorter duration of DAPT was preferable, and therefore, a length of 3 months was prescribed. This approach is aligned with clinical guidelines that emphasize minimizing bleeding risk while still providing adequate protection against thrombotic events. The choice of 3 months allows for effective platelet inhibition during the critical early period after stent placement, while addressing concerns about the increased susceptibility to bleeding by limiting the duration of antiplatelet therapy.

The EVOLVE trial specifically evaluated dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary interventions, focusing on the balance between the risks of thrombotic events and bleeding complications. For high bleeding risk patients, the trial showed that a shorter duration of DAPT was preferable, and therefore, a length of 3 months was prescribed. This approach is aligned with clinical guidelines that emphasize minimizing bleeding risk while still providing adequate protection against thrombotic events. The choice of 3 months allows for effective platelet inhibition during the critical early period after stent placement, while addressing concerns about the increased susceptibility to bleeding by limiting the duration of antiplatelet therapy.

More Multiple Choice Questions
Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy